<tei>
    <teiHeader>
        <fileDesc xml:id="_Maurer 2018.pdf"/>
    </teiHeader>
    <text xml:lang="en">


		<figure type="table">

            <figDesc>The New England Journal of Medicine<lb/> Downloaded from nejm.org on November 9, 2022. For personal use only. No other uses without permission.<lb/> Copyright © 2018 Massachusetts Medical Society. All rights reserved.<lb/> </figDesc>
<lb/> 
            <table>tors. All authors participated in the interpreta-<lb/>tion of the data and vouch for the accuracy and<lb/> completeness of the data and for the fidelity of<lb/> the trial to the protocol, available with the full<lb/> text of this article at NEJM.org. The first author<lb/> wrote the first draft. All authors participated in<lb/> manuscript development and made the decision<lb/> to publish the results. Agreements between the<lb/> sponsor of the trial, Pfizer, and the investigators<lb/> included data confidentiality.<lb/> Patients<lb/> Patients between 18 and 90 years of age were<lb/> eligible to participate in ATTR-ACT if they had<lb/> transthyretin amyloid cardiomyopathy (ATTRwt<lb/> or ATTRm) confirmed by the presence of amyloid<lb/> deposits on analysis of biopsy specimens obtained<lb/> from cardiac and noncardiac sites (e.g., fat aspi-<lb/>rate, gastrointestinal sites, salivary glands, or<lb/> bone marrow) and, in patients without ATTRm,<lb/> by the presence of transthyretin precursor pro-<lb/>tein confirmed on immunohistochemical analy-<lb/>sis, scintigraphy, or mass spectrometry. Cardiac<lb/> involvement was confirmed by means of echocar-<lb/>diography, with an end-diastolic interventricular<lb/> septal wall thickness exceeding 12 mm; a history<lb/> of heart failure, with at least one prior hospital-<lb/>ization for heart failure or clinical evidence of<lb/> heart failure (without hospitalization) manifested<lb/> in signs or symptoms of volume overload or ele-<lb/>vated intracardiac pressures requiring treatment<lb/> with a diuretic for improvement; an N-terminal<lb/> </table>
<lb/> 
            <note>pro-B-type natriuretic peptide (NT-proBNP) level<lb/> greater than or equal to 600 pg per milliliter; and<lb/> a 6-minute walk-test distance exceeding 100 m.</note>
		</figure>


		<figure type="table">

            <table>441 Underwent randomization<lb/> 548 Patients were screened<lb/> 107 Were excluded<lb/> 94 Were not eligible<lb/> 13 Withdrew consent<lb/> 264 Were assigned to pooled tafamidis<lb/> and had efficacy assessment<lb/> (intention-to-treat analysis)<lb/> 177 Were assigned to placebo<lb/> and had efficacy assessment<lb/> (intention-to-treat analysis)<lb/> 52 Discontinued study<lb/> 30-mo vital status:<lb/> 33 Died<lb/> 19 Were alive<lb/> 39 Died during the study<lb/> 54 Discontinued study<lb/> 30-mo vital status:<lb/> 34 Died<lb/> 20 Were alive<lb/> 38 Died during the study<lb/> 173 Completed the study<lb/> 85 Completed the study<lb/> </table>
<lb/> 
            <note>The New England Journal of Medicine<lb/> Downloaded from nejm.org on November 9, 2022. For personal use only. No other uses without permission.<lb/> Copyright © 2018 Massachusetts Medical Society. All rights reserved.</note>
		</figure>


		<figure type="table">

            <figDesc>in the<lb/> Supplementary Appendix, available at NEJM.org.).<lb/> Overall, baseline characteristics in the two groups<lb/> were balanced (Table 1, and Table S2 in the Sup-<lb/>plementary Appendix). The median age was 75<lb/> years, and patients were predominately male.<lb/> </figDesc>
<lb/> 
            <table>Characteristic<lb/> Tafamidis<lb/> (N=264)<lb/> Placebo<lb/> (N=177)<lb/> Age -yr<lb/> Mean<lb/> 74.5±7.2<lb/> 74.1±6.7<lb/> Median (range)<lb/> 75 (46-88)<lb/> 74 (51-89)<lb/> Sex -no. (%)<lb/> Male<lb/> 241 (91.3)<lb/> 157 (88.7)<lb/> Female<lb/> 23 (8.7)<lb/> 20 (11.3)<lb/> Race -no. (%)<lb/> White<lb/> 211 (79.9)<lb/> 146 (82.5)<lb/> Black<lb/> 37 (14.0)<lb/> 26 (14.7)<lb/> Asian<lb/> 13 (4.9)<lb/> 5 (2.8)<lb/> Other<lb/> 3 (1.1)<lb/> 0<lb/> TTR genotype -no. (%)<lb/> ATTRm<lb/> 63 (23.9)<lb/> 43 (24.3)<lb/> ATTRwt<lb/> 201 (76.1)<lb/> 134 (75.7)<lb/> Blood pressure -mm Hg<lb/> Supine<lb/> Systolic<lb/> 115.4±15.4<lb/> 115.1±15.7<lb/> Diastolic<lb/> 70.4±10.3<lb/> 70.2±9.5<lb/> Standing<lb/> Systolic<lb/> 115.5±15.5<lb/> 115.9±15.9<lb/> Diastolic<lb/> 70.6±9.9<lb/> 71.0±10.3<lb/> Heart rate, mean -beats per<lb/> minute<lb/> Supine<lb/> 70.7±12.3<lb/> 69.9±11.7<lb/> Standing<lb/> 72.9±12.9<lb/> 73.8±12.2<lb/> NYHA Class -no. (%)<lb/> Class I<lb/> 24 (9.1)<lb/> 13 (7.3)<lb/> Class II<lb/> 162 (61.4)<lb/> 101 (57.1)<lb/> Class III<lb/> 78 (29.5)<lb/> 63 (35.6)<lb/> Modified BMI †<lb/> 1058.8±173.8<lb/> 1066.4±194.4<lb/> NT-proBNP level -pg/ml<lb/> Median<lb/> 2995.9<lb/> 3161.0<lb/> Interquartile range<lb/> 1751.5-4861.5<lb/> 1864.4-4825.0<lb/> * Plus-minus values are means ±SD. There were 264 patients in the tafamidis<lb/> group and 177 patients in the placebo group in both the intention-to-treat and<lb/> safety analyses. Percentages may not total 100 because of rounding. NT-<lb/>proBNP denotes N-terminal pro-B-type natriuretic peptide, and NYHA New<lb/> York Heart Association.<lb/> </table>
<lb/> 
            <note>† The modified body-mass index (BMI) is calculated as the serum albumin level<lb/> in grams per liter multiplied by the conventional BMI (the weight in kilograms<lb/> divided by the square of the height in meters).<lb/> </note>
<lb/> 
            <head>Table </head>
 
            <label>1</label>

            <head>. Demographic and Clinical Characteristics of the Patients<lb/> at Baseline.</head>

            <note>*<lb/> The New England Journal of Medicine<lb/> Downloaded from nejm.org on November 9, 2022. For personal use only. No other uses without permission.<lb/> </note>
<lb/> 
            <table>Copyright © 2018 Massachusetts Medical Society. All rights reserved.<lb/> </table>
<lb/> 
            <note>n engl j med 379;11 nejm.org September 13, 2018</note>
		</figure>


		<figure type="table">

            <table>)<lb/> 216 (48)<lb/> 141 (36)<lb/> 209 (55)<lb/> 131 (46)<lb/> 200 (64)<lb/> 118 (59)<lb/> 193 (71)<lb/> 113 (64)<lb/> 3<lb/> 21<lb/> 24<lb/> 27<lb/> 30<lb/> 0 (78)<lb/> 0 (76)<lb/> 99 (78)<lb/> 51 (75)<lb/> Pooled tafamidis<lb/> Placebo<lb/> Pooled Tafamidis<lb/> Placebo<lb/> 264<lb/> 177<lb/> 186 (70.5)<lb/> 101 (57.1)<lb/> 1.70 (1.26-2.29)<lb/> &lt;0.001<lb/> 0.30<lb/> 0.46<lb/> No. of<lb/> Patients<lb/> Patients Alive<lb/> at Mo 30<lb/> P Value from<lb/> Finkelstein-Schoenfeld<lb/> Method<lb/> Win Ratio<lb/> (95% CI)<lb/> no. (%)<lb/> Average Cardiovascular-Related<lb/> Hospitalizations during 30 Mo<lb/> among Those Alive at Mo 30<lb/> per patient per yr<lb/> Pooled Tafamidis<lb/> Placebo<lb/> 264<lb/> 177<lb/> 0.68 (0.56-0.81)<lb/> 0.48<lb/> 0.70<lb/> 138 (52.3)<lb/> 107 (60.5)<lb/> No. of<lb/> Patients<lb/> No. of Patients with<lb/> Cardiovascular-Related<lb/> Hospitalizations<lb/> Cardiovascular-Related<lb/> Hospitalizations<lb/> Pooled Tafamidis vs. Placebo<lb/> Treatment Difference<lb/> no. per yr<lb/> relative risk ratio (95% CI)<lb/> total no. (%)</table>
		</figure>


		<figure type="table">

            <figDesc>[95% CI, −1249.16 to −221.13]<lb/> at 12 months and −2180.54 [95% CI, −3326.14 to<lb/> −1034.95] at 30 months). Directionally positive<lb/> echocardiographic findings (see Table S4 in the<lb/> Supplementary Appendix), including a smaller de-</figDesc>
		</figure>


		<figure type="table">

            <table>0.50<lb/> 1.00<lb/> 2.00<lb/> Placebo Better<lb/> Tafamidis Better<lb/> Overall -pooled tafamidis<lb/> vs. placebo<lb/> TTR genotype<lb/> ATTRm<lb/> ATTRwt<lb/> NYHA baseline<lb/> Class I or II<lb/> Class III<lb/> Dose<lb/> 80 mg vs. placebo<lb/> 20 mg vs. placebo<lb/> Cardiovascular Hospitalization<lb/> Relative Risk Ratio (95% CI)<lb/> P Value from<lb/> Finkelstein-<lb/>Schoenfeld<lb/> Method<lb/> Survival Analysis<lb/> Hazard Ratio (95% CI)<lb/> Subgroup<lb/> 0.25<lb/> P Value for<lb/> Interaction<lb/> &lt;0.001<lb/> 0.30<lb/> &lt;0.001<lb/> &lt;0.001<lb/> 0.78<lb/> 0.003<lb/> 0.005<lb/> P Value for<lb/> Interaction<lb/> 0.79<lb/> 0.22<lb/> 0.11<lb/> &lt;0.001<lb/> 0.50<lb/> 1.00<lb/> 2.00<lb/> Placebo Better<lb/> Tafamidis Better<lb/> 0.25<lb/> </table>
<lb/> 
            <figDesc>The New England Journal of Medicine<lb/> Downloaded from nejm.org on November 9, 2022. For personal use only. No other uses without permission.<lb/> Copyright © 2018 Massachusetts Medical Society. All rights reserved.</figDesc>
		</figure>



    </text>
</tei>

